Intel stock spikes after report of possible US government stake
LOS ANGELES - Kairos Pharma Ltd. (NYSE American: KAPA), a biopharmaceutical company specializing in cancer treatment therapies, has announced its key milestones from 2024 and provided an outlook for 2025 in a recent Letter to Shareholders. The company's stock, currently trading at $1.73, has shown strong momentum with a 14.5% gain over the past week. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with analysts setting an optimistic price target of $9. The company, known for developing drugs to counteract cancer drug resistance and immune suppression, highlighted its progress and future plans, including clinical trials and the expansion of patent coverage.
In the past year, Kairos Pharma successfully closed its Initial Public Offering (IPO) on September 16, 2024, and began trading on the NYSE American stock exchange. Since then, the stock has demonstrated high volatility, trading between $0.85 and $4.00. InvestingPro subscribers have access to 8 additional key insights about KAPA's trading patterns and financial health. A collaboration with PreCheck Health Services was established to develop a biomarker panel to identify patients responsive to the company's lead candidate, ENV105, for treating prostate and lung cancer drug resistance.
Further advancements in 2024 included the addition of City of Hope Cancer Center to the Phase 2 clinical trial of ENV105 for castrate-resistant prostate cancer, and the commencement of a combination therapy trial of ENV105 with Osimertinib for EGFR-driven lung cancer. The company also raised $3.5 million through a Private Investment in Public Equity (PIPE) transaction to support ongoing clinical trials and preclinical asset development. InvestingPro data shows the company maintains a healthy current ratio of 2.84, with liquid assets exceeding short-term obligations, and minimal debt with a debt-to-equity ratio of just 0.04.
Looking ahead to 2025, Kairos Pharma is set to continue its Phase 2 randomized clinical trial of ENV105 in prostate cancer and its Phase 1 trial in non-small cell lung cancer (NSCLC). Initial safety data from these trials are expected in the first half of 2025 for prostate cancer and by the year's end for NSCLC. With the next earnings report due on February 26, 2025, investors following KAPA on InvestingPro will have access to comprehensive financial analysis and real-time updates on the company's progress. The company also plans to present its data at national scientific meetings and initiate pre-IND studies for another therapeutic candidate, KROS 101.
The CEO of Kairos Pharma, Dr. John Yu, expressed confidence in the potential of their therapeutics, which are based on breakthrough science, to make a significant impact on the treatment of human neoplastic disorders. He also emphasized the company's commitment to providing value to shareholders and advancing their scientific endeavors.
The company's lead candidate, ENV105, is an antibody targeting CD105, a protein linked to resistance to various cancer treatments. By targeting CD105, ENV105 aims to restore the effectiveness of standard therapies across multiple cancer types.
This article is based on a press release statement from Kairos Pharma, which contains forward-looking statements regarding their clinical trials and future performance. These statements are subject to risks and uncertainties, and there is no guarantee that the projected events will occur.
In other recent news, Kairos Pharma raised $3.5 million in a private investment in public equity (PIPE) transaction. The pharmaceutical company issued 2,500,000 common units, each consisting of one common share and one warrant to purchase additional common shares. The transaction also involved the issuance of pre-funded units, each consisting of a pre-funded warrant to purchase one share of common stock and a common warrant to purchase one and one-half shares of common stock. Boustead Securities, LLC and D. Boral (OTC:BOALY) Capital LLC served as co-placement agents for the offering.
Furthermore, Kairos Pharma announced a change in its board of directors with the resignation of Dr. Rosemary Mazanet and the appointment of Dr. Rahul Singhvi. Dr. Singhvi, who has extensive experience in the life sciences industry, will serve on the audit committee and chair the compensation committee and the nominating and corporate governance committee.
Analysts from EF Hutton have set a target price of $9 per share for Kairos Pharma, despite the company's EBITDA of -$1.83 million in the last twelve months. The firm initiated coverage on Kairos Pharma with a Buy rating, highlighting the company's innovative work on immune suppression and drug resistance in the field of cancer therapeutics. These are the recent developments in the company's journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.